Klin Onkol 2004; 17(2): 68-71.
Summary: Soft tissue sarcoma are a heterogenous group of malignancy, which represents about 1% of all malignancy. Doxorubicine and ifosfamide represents the most active drugs for the treatment of advanced or metastatic disease, which achieve response rates about 20-30 %. We treated 20 patients with locally advanced or metastatic soft tissue sarcoma with the combination of doxorubicin 75mg/m2 and ifosfamide 5g/m2 with the uroprotective mesna applied on day one every 3 weeks. Malignant fibrous histiocytoma and leiomyosarcoma were the most offen seen histiological types of STS, and the lung the predominant side of metastatic disaese.The median age was 40 years, the number of males were 9 and females 11. Myelotoxicity grade 3 and 4 was observed in all patients. 5 patients experienced febrile neutropenia. Two patients (10%) achieved complete response, 5 ( 25%) partial response and 7 (35%) patients progressed on the treatment. Median time to progression was 10 months, in two years followup still 40% of patients were alive.We conclude that the combination of doxorubicin and ifosfamide in selected young patients is an acceptable treatment approach with managable hematotoxicity.
